Fluorescent Coagulation Protease Probes for Selective Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective and selective tools for detecting and inhibiting coagulation proteases such as APC, fIIa, and fXa, which are crucial for understanding and treating blood clotting disorders and other diseases, due to the complexity of their signaling pathways and interactions with other proteins.
Innovation Solution
Development of novel compounds, including fluorescent activity-based probes (ABPs) and inhibitors, specifically designed to target and inhibit APC, fIIa, and fXa, utilizing chemical structures with fluorescent groups and reactive binding sites to detect and inhibit these proteases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional detection and inhibition tools are used for coagulation proteases, then existing knowledge can be maintained, but selective detection and inhibition of APC, fIIa, fXa, and fXIa cannot be achieved due to the complexity of their signaling pathways and interactions
Solution Approach 1:
The patent divides the complex coagulation protease system into individual targets (APC, fIIa, fXa, fXIa) and develops separate selective probes and inhibitors for each. This segmentation allows precise detection and inhibition of specific proteases despite the complexity of their signaling pathways and interactions.
Solution Approach 2:
The patent introduces activity-based probes (ABPs) as intermediary molecules that covalently bind to active site residues of coagulation proteases. These probes serve as mediators between the complex protease system and detection methods, enabling selective measurement of protease activity without directly interfering with the complex signaling pathways.
2Loss of information
If comprehensive studies of coagulation proteases are conducted to understand their roles in diseases, then disease mechanisms can be fully elucidated, but the complexity of signaling pathways and protein interactions makes this difficult
Solution Approach 1:
The patent extracts specific functional information about coagulation proteases by using selective inhibitors and probes that isolate individual protease activities from the complex network of protein interactions. This extraction approach enables detailed study of disease mechanisms without being overwhelmed by the complexity of the entire coagulation system.
Solution Approach 2:
The patent changes the detection parameter from direct observation of complex protein interactions to measurement of protease activity through fluorescent probes. By transforming the measurement approach, the patent simplifies the analysis of disease mechanisms while maintaining comprehensive information about protease functions.
3Reliability
If selective probes and inhibitors are developed for coagulation proteases, then detection and inhibition specificity is improved, but the complexity of designing and synthesizing these compounds increases
Solution Approach 1:
The patent develops a universal probe platform based on activity-based probing that can be applied to multiple coagulation proteases (APC, fIIa, fXa, fXIa) with similar chemical mechanisms. This universality simplifies the synthesis process compared to developing entirely new compounds for each protease, while maintaining high specificity through carefully designed reactive groups and protein-specific binding sites.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds provide selective detection and inhibition of coagulation proteases, enabling better understanding of their roles in diseases like hemophilia, thrombosis, and other conditions, and facilitating targeted therapeutic interventions.
Implementation Method 1
R3 is fluorescent group such as: 1-(5-carboxypentyl)-3,3-dimethyl-2-((1E,3Z)-3-(1,3,3-trimethylindolin-2-ylidene) prop-1-enyl)-3H-indolium (Cyanine 3), 1-(5-carboxypentyl)-2-((1E,3E,5E)-5-(1,3-dimethylindolin-2-ylidene) penta-1,3-dienyl)-3,3-dimethyl-3H-indolium (Cyanine 5), 1-(5-carboxypentyl)-3,3-dimethyl-2-((E)-2-((E)-3-((Z)-2-(1,3,3-trimethylindolin-2-ylidene)ethylidene)cyclohex-1-enyl) vinyl)-3H-indolium (Cyanine 7), or 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid (Bodipy)
Data Source
AI summary
The present invention relates to novel compounds suitable for the detection and/or inhibition of coagulation proteases, specifically APC, fIIa, fXa, and fXIa. The compounds have the structural formula 1 or X shown below:in which R1, P1, P2, P3, P4, Z, R1x, A1, A2, A3, A4 and Zx are defined herein.The present invention also relates to compositions comprising the compounds of formula I or formula X defined herein, to processes for synthesising these compounds and to their use for the treatment and/or detection of diseases and conditions in which coagulation proteases, in particular APC, fIIa, fXa, and fXIa, are implicated.